Topline Summary. Immunome, Inc. (NASDAQ:IMNM) is a developmental biopharma developing agents to exploit novel targets in cancer medicine.Their rise since early 2023 has been meteoric, driven by ...

Back to IMNM Overview Call and put options are quoted in a table called a chain sheet. The chain sheet shows the price, volume and open interest for each option strike price and expiration month.

Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Immunome, Inc. (IMNM) shares rallied 6% in the last trading session to close at $9.3. This move can be attributable to notable volume with a higher number of shares being traded than in a typical ...